Adherium (ASX:ADR) develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease. Adherium operates globally from bases in New Zealand, Australia, USA and UK.
The Company is a provider of digital health solutions to pharmaceutical, remote patient monitoring and clinical trials companies and organisations with the Company’s proprietary Smartinhaler™ platform independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.
To learn more, visit www.adherium.com